Breaking Down Alnylam Pharmaceuticals – A Fundamental Overview

By Kim Brooks • Saturday, November 16 10:13 • Permanent Link

One of the losers of today's trading session was Alnylam Pharmaceuticals. Shares of the Pharmaceutical company plunged -8.7%, and some investors may be wondering if its price of $235.56 would make a good entry point. Here's what you should know if you are considering this investment:

Alnylam Pharmaceuticals has moved 42.5% over the last year, and the S&P 500 logged a change of 29.1%
ALNY has an average analyst rating of buy and is -21.84% away from its mean target price of $301.4 per share
Its trailing earnings per share (EPS) is $-2.61
Alnylam Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -90.3 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $-1.22 and its forward P/E ratio is -193.1
The company has a Price to Book (P/B) ratio of 938.49 in contrast to the S&P 500's average ratio of 4.74
Alnylam Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
The company has a free cash flow of $309.57 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.